VTGN [NASD]
VistaGen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own0.20% Shs Outstand206.38M Perf Week-14.15%
Market Cap198.64M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float205.86M Perf Month-10.78%
Income-61.60M PEG- EPS next Q-0.07 Inst Own69.20% Short Float5.26% Perf Quarter-21.55%
Sales1.50M P/S132.43 EPS this Y55.10% Inst Trans-2.48% Short Ratio8.05 Perf Half Y-55.61%
Book/sh0.31 P/B2.94 EPS next Y-27.30% ROA- Target Price7.33 Perf Year-67.96%
Cash/sh0.31 P/C2.92 EPS next 5Y- ROE- 52W Range0.87 - 3.55 Perf YTD-53.33%
Dividend- P/FCF- EPS past 5Y- ROI-73.90% 52W High-74.37% Beta0.97
Dividend %- Quick Ratio12.30 Sales past 5Y-2.40% Gross Margin- 52W Low4.60% ATR0.09
Employees31 Current Ratio12.30 Sales Q/Q14.10% Oper. Margin- RSI (14)37.56 Volatility10.90% 8.91%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.30 Prev Close0.96
ShortableYes LT Debt/Eq0.00 EarningsJun 23 AMC Payout- Avg Volume1.35M Price0.91
Recom1.20 SMA20-12.06% SMA50-21.98% SMA200-46.82% Volume1,738,432 Change-5.21%
May-20-21Initiated Robert W. Baird Outperform $9
Feb-18-21Initiated Jefferies Buy $6
Jan-04-21Upgrade William Blair Mkt Perform → Outperform
Jun-27-18Initiated Maxim Group Buy $6
Feb-08-18Reiterated Chardan Capital Markets Buy $30 → $22
Mar-28-17Initiated Maxim Group Buy $4
Jun-23-22 05:35PM  
04:20PM  
Jun-22-22 08:30AM  
Jun-17-22 08:30AM  
Jun-02-22 08:30AM  
May-31-22 05:20AM  
May-27-22 08:30AM  
May-19-22 06:00PM  
May-10-22 10:34AM  
May-05-22 08:30AM  
May-02-22 08:00AM  
Apr-21-22 08:00AM  
Apr-12-22 02:57PM  
11:20AM  
07:00AM  
Apr-07-22 12:05PM  
Apr-05-22 12:08PM  
Mar-24-22 08:00AM  
Mar-19-22 08:38AM  
Feb-10-22 05:55PM  
04:20PM  
Feb-07-22 08:00AM  
Feb-03-22 03:01PM  
Nov-19-21 11:17AM  
Nov-16-21 08:30AM  
Nov-14-21 08:53AM  
Nov-11-21 04:31AM  
Nov-10-21 07:05PM  
04:20PM  
Nov-04-21 03:01PM  
08:00AM  
Oct-14-21 12:18PM  
08:00AM  
Oct-05-21 12:06PM  
08:00AM  
Sep-20-21 02:38PM  
Sep-13-21 06:00AM  
Sep-08-21 08:00AM  
Aug-13-21 06:31AM  
Aug-12-21 08:05PM  
04:25PM  
Aug-09-21 04:05PM  
Aug-02-21 09:05AM  
08:00AM  
Jul-22-21 08:00AM  
Jul-21-21 08:28AM  
Jul-09-21 08:30AM  
06:54AM  
Jul-07-21 08:30AM  
Jun-30-21 04:14PM  
Jun-29-21 04:15PM  
Jun-25-21 08:00AM  
Jun-16-21 08:00AM  
May-26-21 08:00AM  
May-20-21 08:00AM  
May-19-21 08:37AM  
May-04-21 08:00AM  
Apr-27-21 09:33AM  
08:00AM  
Mar-31-21 10:30PM  
Mar-22-21 08:30AM  
Mar-16-21 07:46AM  
Mar-11-21 08:30AM  
08:17AM  
Feb-18-21 12:00PM  
10:02AM  
Feb-15-21 08:05AM  
Feb-11-21 05:55PM  
04:30PM  
Jan-06-21 08:00AM  
Dec-30-20 09:00AM  
Dec-22-20 04:01PM  
Dec-18-20 06:25AM  
Dec-17-20 04:01PM  
Dec-10-20 08:30AM  
Dec-01-20 08:30AM  
Nov-19-20 10:58AM  
Nov-16-20 03:07AM  
Nov-12-20 05:25PM  
08:30AM  
Oct-27-20 08:17AM  
Oct-14-20 08:30AM  
Sep-03-20 08:30AM  
Aug-31-20 05:00PM  
Aug-27-20 08:30AM  
Aug-13-20 04:30PM  
Aug-10-20 08:30AM  
Aug-05-20 08:12AM  
Jul-23-20 08:00AM  
Jun-29-20 05:16PM  
Jun-25-20 08:00AM  
May-27-20 08:00AM  
May-18-20 08:05AM  
Apr-29-20 10:35AM  
Apr-28-20 09:15AM  
Mar-25-20 09:00AM  
Feb-20-20 08:30AM  
Feb-13-20 04:30PM  
Feb-11-20 08:30AM  
Jan-30-20 08:30AM  
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Singh ShawnCHIEF EXECUTIVE OFFICERMay 12Option Exercise1.00100,000100,000148,998May 16 01:39 PM
DOTSON JERROLD DUANEVP, CFO AND SECRETARYJan 11Option Exercise1.0018,75018,75094,571Jan 12 05:21 PM
DOTSON JERROLD DUANEVP, CFO AND SECRETARYSep 07Sale3.1230,00093,75072,786Sep 08 06:58 PM
SNODGRASS H. RALPHPRES./CHIEF SCIENTIFIC OFFICERAug 17Buy2.733,75010,23834,641Aug 18 06:20 PM